JP2016500660A5 - - Google Patents

Download PDF

Info

Publication number: JP2016500660A5
Authority: JP; Japan
Prior art keywords: capromorelin; composition; companion animal; oral; pharmaceutical composition
Prior art date: 2013-09-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP2015534747A

Other languages

English (en)

Japanese (ja)

Other versions

JP2016500660A (ja

JP6779618B2 (ja

Filing date

2013-09-27

Publication date

2016-11-10

2013-09-27 Application filed filed Critical

2013-09-27 Priority claimed from PCT/US2013/062227 external-priority patent/WO2014052780A2/en

2016-01-14 Publication of JP2016500660A publication Critical patent/JP2016500660A/ja

2016-11-10 Publication of JP2016500660A5 publication Critical patent/JP2016500660A5/ja

2020-11-04 Application granted granted Critical

2020-11-04 Publication of JP6779618B2 publication Critical patent/JP6779618B2/ja

Status Active legal-status Critical Current

2033-09-27 Anticipated expiration legal-status Critical

Links

KVLLHLWBPNCVNR-SKCUWOTOSA-N capromorelin Chemical compound C([C@@]12CN(CCC1=NN(C2=O)C)C(=O)[C@@H](COCC=1C=CC=CC=1)NC(=O)C(C)(C)N)C1=CC=CC=C1 KVLLHLWBPNCVNR-SKCUWOTOSA-N 0.000 claims 47
229950004826 capromorelin Drugs 0.000 claims 47
239000000203 mixture Substances 0.000 claims 27
241001465754 Metazoa Species 0.000 claims 26
238000000034 method Methods 0.000 claims 25
239000008203 oral pharmaceutical composition Substances 0.000 claims 17
230000037396 body weight Effects 0.000 claims 12
235000003599 food sweetener Nutrition 0.000 claims 9
239000003765 sweetening agent Substances 0.000 claims 9
HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 claims 8
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 6
208000022531 anorexia Diseases 0.000 claims 6
206010061428 decreased appetite Diseases 0.000 claims 6
239000001329 FEMA 3811 Substances 0.000 claims 5
239000001512 FEMA 4601 Substances 0.000 claims 5
VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 claims 5
239000005913 Maltodextrin Substances 0.000 claims 5
229920002774 Maltodextrin Polymers 0.000 claims 5
ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 claims 5
HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 claims 5
239000004376 Sucralose Substances 0.000 claims 5
HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 claims 5
LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims 5
239000001685 glycyrrhizic acid Substances 0.000 claims 5
229960004949 glycyrrhizic acid Drugs 0.000 claims 5
UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims 5
235000019410 glycyrrhizin Nutrition 0.000 claims 5
LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims 5
229940035034 maltodextrin Drugs 0.000 claims 5
ITVGXXMINPYUHD-CUVHLRMHSA-N neohesperidin dihydrochalcone Chemical compound C1=C(O)C(OC)=CC=C1CCC(=O)C(C(=C1)O)=C(O)C=C1O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ITVGXXMINPYUHD-CUVHLRMHSA-N 0.000 claims 5
229940089953 neohesperidin dihydrochalcone Drugs 0.000 claims 5
235000010434 neohesperidine DC Nutrition 0.000 claims 5
235000019203 rebaudioside A Nutrition 0.000 claims 5
235000019408 sucralose Nutrition 0.000 claims 5
BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims 5
239000000892 thaumatin Substances 0.000 claims 5
235000010436 thaumatin Nutrition 0.000 claims 5
235000009499 Vanilla fragrans Nutrition 0.000 claims 4
244000263375 Vanilla tahitensis Species 0.000 claims 4
235000012036 Vanilla tahitensis Nutrition 0.000 claims 4
235000013305 food Nutrition 0.000 claims 4
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 4
230000001965 increasing effect Effects 0.000 claims 4
239000003550 marker Substances 0.000 claims 4
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims 4
230000004580 weight loss Effects 0.000 claims 4
244000228451 Stevia rebaudiana Species 0.000 claims 3
239000007788 liquid Substances 0.000 claims 3
244000144972 livestock Species 0.000 claims 3
239000002207 metabolite Substances 0.000 claims 3
SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 2
239000005715 Fructose Substances 0.000 claims 2
229930091371 Fructose Natural products 0.000 claims 2
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
241000202807 Glycyrrhiza Species 0.000 claims 2
235000001453 Glycyrrhiza echinata Nutrition 0.000 claims 2
235000006200 Glycyrrhiza glabra Nutrition 0.000 claims 2
235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims 2
101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 2
102100037852 Insulin-like growth factor I Human genes 0.000 claims 2
239000004384 Neotame Substances 0.000 claims 2
239000004383 Steviol glycoside Substances 0.000 claims 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 2
229930006000 Sucrose Natural products 0.000 claims 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 2
230000017531 blood circulation Effects 0.000 claims 2
239000003995 emulsifying agent Substances 0.000 claims 2
230000037406 food intake Effects 0.000 claims 2
235000012631 food intake Nutrition 0.000 claims 2
239000008103 glucose Substances 0.000 claims 2
235000011187 glycerol Nutrition 0.000 claims 2
229960000890 hydrocortisone Drugs 0.000 claims 2
239000000905 isomalt Substances 0.000 claims 2
235000010439 isomalt Nutrition 0.000 claims 2
HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims 2
229940010454 licorice Drugs 0.000 claims 2
239000000845 maltitol Substances 0.000 claims 2
235000010449 maltitol Nutrition 0.000 claims 2
VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims 2
229940035436 maltitol Drugs 0.000 claims 2
210000003205 muscle Anatomy 0.000 claims 2
235000019412 neotame Nutrition 0.000 claims 2
HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 claims 2
108010070257 neotame Proteins 0.000 claims 2
239000006186 oral dosage form Substances 0.000 claims 2
239000000243 solution Substances 0.000 claims 2
239000000600 sorbitol Substances 0.000 claims 2
235000010356 sorbitol Nutrition 0.000 claims 2
235000019411 steviol glycoside Nutrition 0.000 claims 2
229930182488 steviol glycoside Natural products 0.000 claims 2
150000008144 steviol glycosides Chemical class 0.000 claims 2
235000019202 steviosides Nutrition 0.000 claims 2
239000005720 sucrose Substances 0.000 claims 2
239000002562 thickening agent Substances 0.000 claims 2
FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 claims 1
241000282326 Felis catus Species 0.000 claims 1
230000003247 decreasing effect Effects 0.000 claims 1
208000010706 fatty liver disease Diseases 0.000 claims 1
239000004615 ingredient Substances 0.000 claims 1
229940085605 saccharin sodium Drugs 0.000 claims 1
239000012266 salt solution Substances 0.000 claims 1
238000005507 spraying Methods 0.000 claims 1
239000000725 suspension Substances 0.000 claims 1
230000004584 weight gain Effects 0.000 claims 1
235000019786 weight gain Nutrition 0.000 claims 1

JP2015534747A 2012-09-27 2013-09-27 食欲不振制御化合物の組成物および使用方法 Active JP6779618B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201261706164P	2012-09-27	2012-09-27
US61/706,164		2012-09-27
PCT/US2013/062227 WO2014052780A2 (en)	2012-09-27	2013-09-27	Compositions and methods of use of an inappetance-controlling compound

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2018041063A Division JP6796097B2 (ja)	2012-09-27	2018-03-07	食欲不振制御化合物の組成物および使用方法

Publications (3)

Publication Number	Publication Date
JP2016500660A JP2016500660A (ja)	2016-01-14
JP2016500660A5 true JP2016500660A5 (2)	2016-11-10
JP6779618B2 JP6779618B2 (ja)	2020-11-04

Family

ID=50339468

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
JP2015534747A Active JP6779618B2 (ja)	2012-09-27	2013-09-27	食欲不振制御化合物の組成物および使用方法
JP2018041063A Active JP6796097B2 (ja)	2012-09-27	2018-03-07	食欲不振制御化合物の組成物および使用方法

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
JP2018041063A Active JP6796097B2 (ja)	2012-09-27	2018-03-07	食欲不振制御化合物の組成物および使用方法

Country Status (18)

Country	Link
US (1)	US11090292B2 (2)
EP (3)	EP3524260B1 (2)
JP (2)	JP6779618B2 (2)
KR (6)	KR20250048114A (2)
CN (2)	CN105072909A (2)
AR (2)	AR092713A1 (2)
AU (2)	AU2013323349B2 (2)
BR (1)	BR112015006282B1 (2)
CA (1)	CA2886091C (2)
DK (1)	DK3524260T3 (2)
ES (1)	ES2959427T3 (2)
MX (2)	MX2015003564A (2)
NZ (2)	NZ707174A (2)
PL (1)	PL3524260T3 (2)
PT (1)	PT3524260T (2)
RU (1)	RU2648958C2 (2)
TW (3)	TWI732158B (2)
WO (1)	WO2014052780A2 (2)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPWO2011105611A1 (ja)	2010-02-26	2013-06-20	ラクオリア創薬株式会社	悪液質を治療するためのグレリン受容体作動物質
US10039813B2 (en)	2012-02-07	2018-08-07	Massachusetts Institute Of Technology	Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
TWI732158B (zh)	2012-09-27	2021-07-01	美商雅瑞塔那醫療公司	使用食慾喪失控制化合物之組合物及方法
WO2014144231A1 (en)	2013-03-15	2014-09-18	Massachusetts Institute Of Technology	Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
ES2902795T3 (es) *	2015-01-28	2022-03-29	Elanco Animal Health Incorporated	Composición para uso crónico como compuesto para aumentar de peso
WO2016138099A1 (en)	2015-02-24	2016-09-01	Massachusetts Institute Of Technology	Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
CN110022688A (zh) *	2016-11-11	2019-07-16	希尔氏宠物营养品公司	宠物食物的组合物和方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US193273A (en) *		1877-07-17		Improvement in material for pulley-covers
JP2893901B2 (ja) *	1990-09-07	1999-05-24	株式会社岐阜免疫研究所	動物用抗体含有油性ペースト製剤
CA2095786A1 (en)	1992-05-08	1993-11-09	Franco J. Vaccarino	Method of stimulating appetite
TW432073B (en)	1995-12-28	2001-05-01	Pfizer	Pyrazolopyridine compounds
ATE446758T1 (de)	2000-05-31	2009-11-15	Pfizer Prod Inc	Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts
EP1181933A3 (en) *	2000-06-29	2002-04-10	Pfizer Products Inc.	Use of growth hormone secretagogues for stimulating or increasing appetite
US8309603B2 (en) *	2004-06-07	2012-11-13	University Of Tennessee Research Foundation	SARMs and method of use thereof
US7476653B2 (en) *	2003-06-18	2009-01-13	Tranzyme Pharma, Inc.	Macrocyclic modulators of the ghrelin receptor
US7491695B2 (en) *	2003-06-18	2009-02-17	Tranzyme Pharma Inc.	Methods of using macrocyclic modulators of the ghrelin receptor
JP2007532495A (ja) *	2004-04-07	2007-11-15	ガストロテック・ファルマ・アクティーゼルスカブ	グレリン欠乏を治療するための分泌促進薬の使用
EP1812045A2 (en) *	2004-10-27	2007-08-01	Gastrotech Pharma A/S	Uses of secretagogues for treatment of organ transplant patients
AU2006310690B2 (en) *	2005-11-02	2012-05-31	Société des Produits Nestlé S.A.	Isoflavone compositions for reducing accumulation of body fat in male mammals, and methods for their use
BRPI0708895A2 (pt) *	2006-03-13	2011-06-28	Liat Mintz	uso de variante de junção de grelina para tratar caquexia e/ou anorexia e/ou anorexia-caquexia e/ou subnutrição e/ou lipodistrofia e/ou atrofia muscular e/ou estimulação do apetite
AU2007300526B2 (en) *	2006-09-27	2011-07-21	Ipsen Pharma S.A.S.	Analogs of ghrelin substituted at the N-terminal
JP2008127377A (ja) *	2006-11-24	2008-06-05	Jichi Medical Univ	Ｇｈｓ−ｒ作動薬を含有してなるメタボリックシンドローム又は高血圧症の予防・治療剤。
US20080226802A1 (en) *	2007-03-14	2008-09-18	Concentrate Manufacturing Company Of Ireland	Beverage having natural sweeteners with one or more stevia components and source of berry
TWI429436B (zh) *	2007-04-10	2014-03-11	Helsinn Therapeutics Us Inc	使用生長激素促泌素治療或預防嘔吐之方法
RU2007129408A (ru) *	2007-07-31	2009-02-10	Игорь Николаевич Жирков (RU)	Способ выращивания поросят в период откорма
FR2920295B1 (fr)	2007-09-05	2009-12-11	Desvac	Dispositif d'injection de produits veterinaires a des volailles, comprenant un element de contention presentant une forme anatomique incluant des moyens de calage d'un os reperable
KR101531202B1 (ko) *	2007-11-12	2015-06-24	산에이겐 에후.에후. 아이. 가부시키가이샤	스테비아 추출물의 감미질 개선
SG174476A1 (en) *	2009-03-26	2011-10-28	Takeda Pharmaceutical	Pyrazole compound
JPWO2011105611A1 (ja) *	2010-02-26	2013-06-20	ラクオリア創薬株式会社	悪液質を治療するためのグレリン受容体作動物質
TWI732158B (zh)	2012-09-27	2021-07-01	美商雅瑞塔那醫療公司	使用食慾喪失控制化合物之組合物及方法

2013
- 2013-09-27 TW TW107142255A patent/TWI732158B/zh active
- 2013-09-27 BR BR112015006282-2A patent/BR112015006282B1/pt active IP Right Grant
- 2013-09-27 KR KR1020257009208A patent/KR20250048114A/ko active Pending
- 2013-09-27 KR KR1020197037811A patent/KR20190143484A/ko not_active Ceased
- 2013-09-27 JP JP2015534747A patent/JP6779618B2/ja active Active
- 2013-09-27 AR ARP130103486A patent/AR092713A1/es not_active Application Discontinuation
- 2013-09-27 NZ NZ707174A patent/NZ707174A/en active IP Right Revival
- 2013-09-27 CN CN201380061931.6A patent/CN105072909A/zh active Pending
- 2013-09-27 KR KR1020157009647A patent/KR20150058345A/ko not_active Ceased
- 2013-09-27 RU RU2015114996A patent/RU2648958C2/ru active
- 2013-09-27 TW TW102135177A patent/TWI667024B/zh active
- 2013-09-27 NZ NZ746394A patent/NZ746394A/en unknown
- 2013-09-27 KR KR1020217042990A patent/KR20220003640A/ko not_active Ceased
- 2013-09-27 CN CN202010001164.1A patent/CN111419845A/zh active Pending
- 2013-09-27 AU AU2013323349A patent/AU2013323349B2/en active Active
- 2013-09-27 WO PCT/US2013/062227 patent/WO2014052780A2/en not_active Ceased
- 2013-09-27 MX MX2015003564A patent/MX2015003564A/es active IP Right Grant
- 2013-09-27 ES ES19161662T patent/ES2959427T3/es active Active
- 2013-09-27 US US14/039,114 patent/US11090292B2/en active Active
- 2013-09-27 KR KR1020237019962A patent/KR20230097201A/ko not_active Ceased
- 2013-09-27 KR KR1020217001509A patent/KR20210009438A/ko not_active Ceased
- 2013-09-27 TW TW109121986A patent/TW202106298A/zh unknown
- 2013-09-27 EP EP19161662.2A patent/EP3524260B1/en active Active
- 2013-09-27 EP EP13841455.2A patent/EP2906041A4/en not_active Withdrawn
- 2013-09-27 DK DK19161662.2T patent/DK3524260T3/da active
- 2013-09-27 PT PT191616622T patent/PT3524260T/pt unknown
- 2013-09-27 PL PL19161662.2T patent/PL3524260T3/pl unknown
- 2013-09-27 EP EP23191187.6A patent/EP4302825A3/en active Pending
- 2013-09-27 CA CA2886091A patent/CA2886091C/en active Active
2015
- 2015-03-19 MX MX2022015141A patent/MX2022015141A/es unknown
2016
- 2016-08-22 AU AU2016216741A patent/AU2016216741B2/en active Active
2018
- 2018-03-07 JP JP2018041063A patent/JP6796097B2/ja active Active
2021
- 2021-10-22 AR ARP210102942A patent/AR123902A2/es unknown

Publication	Publication Date	Title
JP2016500660A5 (2)	2016-11-10
Krautwald-Junghanns et al.	2015	Aspergillosis in birds: an overview of treatment options and regimens
JP2010504337A (ja)	2010-02-12	イヌの認知機能障害症候群の治療のためのディメボン（ｄｉｍｅｂｏｎ）などの水素化ピリド［４，３−ｂ］インドール
RU2015114996A (ru)	2016-11-20	Композиции и способы применения соединения для борьбы с отсутствием аппетита
US8722115B2 (en)	2014-05-13	Methods for improving health in animals
HRP20180774T1 (hr)	2018-08-10	Orodisperzibilni dezmopresin za povećanje početnog razdoblja sna neometanog s nokturijom
US10117890B2 (en)	2018-11-06	Methods and compositions for treating pain
JP2017534613A (ja)	2017-11-24	デクスメデトミジン製剤を使用する睡眠障害の予防または治療
JP2016525548A5 (2)	2017-08-31
US20240285576A1 (en)	2024-08-29	R-mdma for treatment of pain
KR20090014183A (ko)	2009-02-06	액상 약제학적 제제
CN103751201A (zh)	2014-04-30	一种犬、猫用抗寄生虫口服崩解片及其制备方法
Söderman et al.	2011	Activation of nicotinic α7 acetylcholine receptor enhances long term potentation in wild type mice but not in APPswe/PS1ΔE9 mice
US20150320783A1 (en)	2015-11-12	N-methylserotonin and related substances for use in treating / lessening the occurrence of hot flashes related to menopause
EP3366288B1 (en)	2023-12-27	Lithium ascorbate exhibiting anti-stress, anxiolytic and anti-depression activity
CN101129188A (zh)	2008-02-27	一种水飞蓟素咀嚼片及其制备方法
CN105263481A (zh)	2016-01-20	使用薄荷醇和/或冰素治疗或预防抑郁
JP6914256B2 (ja)	2021-08-04	膵臓脂肪浸潤を予防または治療し、膵臓脂肪浸潤に起因する膵臓病変、糖尿病または他の関連症状を緩和するための組成物、および方法
KR101783306B1 (ko)	2017-09-29	ＰＤＫｓ 억제제를 유효성분으로 함유하는 알러지성 질환의 예방 또는 치료용 약학적 조성물
JP2017513866A5 (2)	2019-04-25
US20100227891A1 (en)	2010-09-09	Threshold blood omeprazole concentration is 50 ng/ml for the maintenance of intragastric ph of at least 4.0 after oral dosing with cma-omeprazole, agn 201904-z
CN115671106B (zh)	2024-03-19	吗啡的应用
CN102274512A (zh)	2011-12-14	LXR激动剂刺激巨噬细胞干扰素γ表达、抑制肿瘤生长
JP7181695B2 (ja)	2022-12-01	抗認知症剤及び短期記憶障害改善／抑制剤
RU2428194C1 (ru)	2011-09-10	Средство для лечения желудочно-кишечных заболеваний животных